Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-24

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 73

Registration Number: NCT00003004

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-21

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00003101

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 4 locations

Temozolomide in Treating Patients With Recurrent Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-21

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004113

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vaccine Therapy in Treating Patients With Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: MUC1-KLH vaccine/QS21

First Posted Date: 2004-05-20

Last Posted Date: 2013-10-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT00004156

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-20

Last Posted Date: 2013-12-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00004051

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-05-20

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005814

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Not Applicable

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-19

Last Posted Date: 2013-01-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT00082836

Locations: 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States

Massage Therapy in Treating Patients With Cancer Pain

Phase 2

Completed

Conditions: Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: period of quiet time
Other: massage therapy
Other: visit with a volunteer
Behavioral: questionaire about pain

First Posted Date: 2004-05-06

Last Posted Date: 2015-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 92

Registration Number: NCT00082290

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-05-05

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00008255

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-05-04

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00008242

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy